Deferasirox

Deferasirox Dispersible Tablets (180mg, 250mg, 360mg, 400mg, 500mg) is an oral tridentate iron-chelating agent on the WHO Model List of Essential Medicines. It selectively binds ferric iron (Fe3+) in a 2:1 ratio, promoting fecal iron excretion and clearing excessive toxic systemic iron stores without redistributing iron to the brain. Indicated for treatment of chronic iron overload due to frequent blood transfusions in patients with beta-thalassemia major, sickle cell disease, and other chronic anemias (age >=2 years), and non-transfusion-dependent thalassemia syndromes.

Deferasirox Dispersible Tablets (180mg, 250mg, 360mg, 400mg, 500mg) is an oral tridentate iron-chelating agent on the WHO Model List of Essential Medicines. It selectively binds ferric iron (Fe3+) in a 2:1 ratio, promoting fecal iron excretion and clearing excessive toxic systemic iron stores without redistributing iron to the brain. Indicated for treatment of chronic iron overload due to frequent blood transfusions in patients with beta-thalassemia major, sickle cell disease, and other chronic anemias (age >=2 years), and non-transfusion-dependent thalassemia syndromes.

Deferasirox Dispersible Tablets (180mg, 250mg, 360mg, 400mg, 500mg) is an oral tridentate iron-chelating agent on the WHO Model List of Essential Medicines. It selectively binds ferric iron (Fe3+) in a 2:1 ratio, promoting fecal iron excretion and clearing excessive toxic systemic iron stores without redistributing iron to the brain. Indicated for treatment of chronic iron overload due to frequent blood transfusions in patients with beta-thalassemia major, sickle cell disease, and other chronic anemias (age >=2 years), and non-transfusion-dependent thalassemia syndromes.

Deferasirox Dispersible Tablets (180mg, 250mg, 360mg, 400mg, 500mg) is an oral tridentate iron-chelating agent on the WHO Model List of Essential Medicines. It selectively binds ferric iron (Fe3+) in a 2:1 ratio, promoting fecal iron excretion and clearing excessive toxic systemic iron stores without redistributing iron to the brain. Indicated for treatment of chronic iron overload due to frequent blood transfusions in patients with beta-thalassemia major, sickle cell disease, and other chronic anemias (age >=2 years), and non-transfusion-dependent thalassemia syndromes.

Deferasirox Dispersible Tablets (180mg, 250mg, 360mg, 400mg, 500mg) is an oral tridentate iron-chelating agent on the WHO Model List of Essential Medicines. It selectively binds ferric iron (Fe3+) in a 2:1 ratio, promoting fecal iron excretion and clearing excessive toxic systemic iron stores without redistributing iron to the brain. Indicated for treatment of chronic iron overload due to frequent blood transfusions in patients with beta-thalassemia major, sickle cell disease, and other chronic anemias (age >=2 years), and non-transfusion-dependent thalassemia syndromes.